Medicina (Florence, Italy) 1989-01-01

[Nizatidine].

M Romero, M G Franzosi

Index: Medicina (Firenze.) 9(1) , 93-6, (1989)

Full Text: HTML

Abstract

Nizatidine is a new H2-receptor antagonist, as potent as ranitidine. It does not interfere with hepatic metabolism and it lacks anti-androgenic effects. An evening dose of 300 mg suppresses nocturnal acid secretion without diurnal carryover. Published clinical trials are limited. Over 3800 patients who have been treated with nizatidine, 300 mg for up to eight weeks or 150 mg at night for a year, did not appear to have significantly unexpected or unwanted side effects. Rate of healing for both duodenal and gastric ulcers and reduction in the rate of relapse are comparable to those of ranitidine.


Related Compounds

Related Articles:

Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients.

2013-08-01

[J. Gastroenterol. Hepatol. 28(8) , 1314-20, (2013)]

Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying.

2012-01-01

[Digestion 86(2) , 114-21, (2012)]

Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.

2010-04-01

[Clin. Ther. 32(4) , 678-90, (2010)]

Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.

2006-12-01

[Rev. Bras. Psiquiatr. 28(4) , 270-6, (2006)]

Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.

2009-01-01

[BMC Psychiatry 9 , 12, (2009)]

More Articles...